US OptionsDetailed Quotes
PRQR250117C7500
- 0.05
- 0.000.00%
15min DelayClose Jan 8 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume357 Open Interest7.50Strike Price0.00Turnover414.58%IV188.17%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0842Delta0.0948Gamma52.40Leverage Ratio-0.0145Theta0.0000Rho4.41Eff Leverage0.0006Vega
ProQR Therapeutics Stock Discussion
Singapore, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Webuy Global Ltd. (NASDAQ:WBUY) ("Webuy" or the "Company"), a Southeast Asian community e-commerce innovator, is thrilled to announce the launch of its cutting-edge Travel AI, Micky1.0. This tool, available through WhatsApp, helps simplify travel planning and provides personalized support whenever and wherever it is needed.
With just a WhatsApp number, users can interact with Micky1.0 to get immediate answers to the...
ProQR Therapeutics Announces $8.1 Million in New Funding From Rett Syndrome Research Trust to Expand Rna Editing Collaboration
📊⚡️📊
big offering watchout
NEWS
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing technology platform, including the first preclinical data for its AX-0810 pipelin...
No comment yet